Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Procrit Pricing Practices Stabilize Sales, Position Product For Rebound

Executive Summary

J&J pricing strategies have stabilized Procrit sales, possibly positioning the struggling franchise for a rebound, CEO William Weldon stated

You may also be interested in...



J&J Open To Large-Scale Mergers; Still Prefers Centocor, Alza-Sized Deals

Johnson & Johnson is open to deals larger than the $10.5 bil. Alza acquisition, CEO William Weldon said Jan. 20

J&J Open To Large-Scale Mergers; Still Prefers Centocor, Alza-Sized Deals

Johnson & Johnson is open to deals larger than the $10.5 bil. Alza acquisition, CEO William Weldon said Jan. 20

J&J Topamax “Dear Doctor” Letter Advises Metabolic Acidosis Monitoring

Physicians should periodically examine Topamax (topiramate) patients for metabolic acidosis, a Johnson & Johnson "Dear Health Care Professional" letter recommends

Related Content

UsernamePublicRestriction

Register

PS043215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel